By Christy Santhosh Sept 22 (Reuters) - Amgen said on Tuesday its experimental drug to treat an autoimmune disease that ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Morgan Stanley met with Amgen management after Novartis's pelacarsen trial failure. The bank sees a real edge for AMGN's ...

Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment ...

Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning.

Both Amgen and Merck write quarterly checks and raise them every year, but only one has the portfolio depth to keep growing ...

An investigational drug for the autoimmune condition Sjögren's disease has scored a phase 3 win for Amgen, marking a positive ...

Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.

Amgen (AMGN) stock rises after Phase 3 trial win for dazodalibep, an experimental therapy for an autoimmune condition called Sjögren's disease. Read more here.

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.